ABSTRACT
Epidermal growth factor receptor 2 (HER2) is an oncogene involved in tumour genesis and progression. It is expressed in 7% of patients with colorectal cancer (CRC) and is associated with drug resistance of epidermal growth factor receptor monoclonal antibodies. With the emergence of the therapeutic dilemma of CRC and the survival benefits of targeting HER2 for patients with breast cancer and gastric cancer, the significance of HER2 in CRC and the prognostic value of anti-HER2 therapy have been widely concerned, clinical researches on HER2-positive CRC have been continuously carried out. Currently, the diagnostic criteria for HER2 positive CRC have gradually been unified. HER2-targeting therapies such as monoclonal antibodies, tyrosine kinase inhibitors, antibody-drug coupling and HER2-related immunotherapy alone or in combination have shown good efficacy and brought significant survival benefits for HER2 positive CRC. This paper reviews the research progress of HER2 in CRC.
ABSTRACT
Objective:To explore the changes and possible mechanisms of circulating Tc 17 cells in patients with colorectal cancer ( CRC) following disease progression .Methods:The peripheral blood were collected from 54 patients with colorectal cancer . the proportions of Tc17 cells in peripheral blood mononuclear cells (PBMCs) and cultured PBMCs treated by IL-1β, IL-6 and TGF-βin different concentrations were determined by flow cytometry;the levels of IL-1β, IL-17A, IL-23 and IL-6 in sera were measured by ELISA.Results:The proportions of Tc17 cells and the levels of IL-1β, IL-17A, IL-23 and IL-6 were significantly higher than those in healthy controls (P0.05).In vitro experiments confirmed that IL-1βor high concentrations of IL-6 and TGF-βcould significantly increase the number of Tc 17 cells in PBMCs.Conclusion: The changes of circulating Tc 17 cells in the progression of colorectal cancer are possibly modulated by IL-1β, IL-23, IL-6 and TGF-β.
ABSTRACT
Objective To study the expression of CDX2 and p21~(WAF1) protein in colorectal cancer and its correlation with the progression of colorectal cancer., and to explore the eorrelativity of CDX2 and p21~(WAF1) genes expression with TCM deficiency Syndrome. Methods Immunohistochemical method was used to detect the expressions of CDX2 and p21~(WAF1) in45 patients of colorectal carcinoma tissues and peri-cancerous tissues, who received the treatment at the People's Hospital of Jiuquan City between April, 2000 and August, 2005. According to TCM syndrome differentiation, the patients were divided into sthenia syndrome group and asthenia syndrome group and sthenia-ashenia syndrome group. Analyze the Correlation between CDX2 and p21~(WAF1) expression and TCM syndrome. Results The positive rate of CDX2 and p21~(WAF1) was 86.7% and 35.6% respectively in colorectal carcinoma tissues. There was no correlation between CDX2 and p21~(WAF1) in colorectal cancer tissues. The positive rate of p21~(WAF1) was different in three groups, which was much lower in the asthenia syndrome group (11.76%) than the sthenia syndrome group (41.67%)and sthenia-asthenia syndrome group (56.25%). Conclusion CDX2 and p21~(WAF1) positive rate was different in cancer tissue and resection margin. The two genes may be associated with colorectal cancer development. CDX2 was not correlated with p21~(WAF1). The lower expression of p21~(WAF1) indicates poor prognosis. The positive rate of p21~(WAF1) was different between deficiency syndrome and excess syndrome, p21~(WAF1) is probably a marker to determine the asthenia and sthenia syndrome. Asthenia syndrome indicates a poor prognosis.